Insider · CIK 0001537370

Gupta Rishi

Reports to the SEC for 6 companies · BOULDER, CO

sec.gov

Transactions

Companies

Filings

CIK

0001537370

Forms 4 and 5

Insider transactions

40 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-12	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+1,580 sh	—	—	1,580
2026-02-12	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+34K sh	—	—	33,989
2025-08-08	Turnstone Biologics Corp.U Disposition from Tender	Director	UDisposition from Tender	−3.1M sh	—	—	0
2025-02-06	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20.5K sh	—	—	20,491
2024-06-03	Turnstone Biologics Corp.Stock Option (Right to Buy)A Award	Director	AAward	+12.8K sh	—	—	12,770
2024-05-16	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−1M sh	$22.14	−$22.1M	7,663,349
2024-05-16	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−33.3K sh	$22.14	−$737K	254,814
2024-02-13	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+23.4K sh	—	—	23,364
2024-02-13	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+16.8K sh	—	—	16,835
2023-10-16	Turnstone Biologics Corp.Stock Option (Right to Buy)A Award	Director	AAward	+25.5K sh	—	—	25,540
2023-07-20	Turnstone Biologics Corp.P Purchase	Director	PPurchase	+417K sh	$12.00	+$5M	3,099,265
2023-07-20	Turnstone Biologics Corp.C Conversion	Director	CConversion	+2.68M sh	—	—	2,682,599
2023-07-20	Turnstone Biologics Corp.Series D Preferred StockC Conversion	Director	CConversion	−229K sh	—	—	0
2023-07-20	Turnstone Biologics Corp.Series C Preferred StockC Conversion	Director	CConversion	−266K sh	—	—	0
2023-07-20	Turnstone Biologics Corp.Series B-2 Preferred StockC Conversion	Director	CConversion	−1.25M sh	—	—	0
2023-07-20	Turnstone Biologics Corp.Series B-1 Preferred StockC Conversion	Director	CConversion	−937K sh	—	—	0
2023-05-17	ELVNEnliven Therapeutics, Inc. · Stock Options (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,125 sh	—	—	0
2023-05-17	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,125 sh	$4.28	+$9,095	8,663,349
2023-05-15	VRNAVerona Pharma plcS Sale	Director	SSale	−345K sh	$20.00	−$6.91M	3,777,778
2023-05-15	VRNAVerona Pharma plcS Sale	Director	SSale	−14.4K sh	$21.96	−$316K	4,123,091
2023-05-12	VRNAVerona Pharma plcS Sale	Director	SSale	−43.2K sh	$21.64	−$935K	4,137,491
2023-05-11	VRNAVerona Pharma plcS Sale	Director	SSale	−80K sh	$22.26	−$1.78M	4,180,691
2023-04-28	VRNAVerona Pharma plc · Share Options (Right to Buy)A Award	Director	AAward	+96K sh	—	—	96,000
2023-02-23	ELVNEnliven Therapeutics, Inc.A Award	Director	AAward	+288K sh	—	—	288,114
2023-02-23	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+27.6K sh	—	—	27,567
2023-02-23	ELVNEnliven Therapeutics, Inc.A Award	Director	AAward	+7.61M sh	—	—	7,611,458
2022-12-23	VRNAVerona Pharma plcS Sale	Director	SSale	−1.12M sh	$23.23	−$25.9M	34,178,520
2022-12-23	VRNAVerona Pharma plcS Sale	Director	SSale	−961K sh	$22.27	−$21.4M	35,294,568
2022-12-23	VRNAVerona Pharma plcS Sale	Director	SSale	−93K sh	$24.11	−$2.24M	34,085,528
2022-12-22	VRNAVerona Pharma plcS Sale	Director	SSale	−3.28M sh	$21.71	−$71.3M	36,940,592
2022-12-22	VRNAVerona Pharma plcS Sale	Director	SSale	−685K sh	$22.07	−$15.1M	36,255,896
2022-04-28	VRNAVerona Pharma plc · Share Options (Right to Buy)A Award	Director	AAward	+200K sh	—	—	200,000
2021-08-09	VRNAVerona Pharma plc · Share Options (Right to Buy)A Award	Director	AAward	+64K sh	—	—	64,000
2016-05-19	Dimension Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+32.1K sh	—	—	32,069
2015-10-27	Dimension Therapeutics, Inc.C Conversion	Director	CConversion	+1.95M sh	—	—	5,197,698
2015-10-27	Dimension Therapeutics, Inc.C Conversion	Director	CConversion	+3.25M sh	—	—	3,250,085
2015-10-27	Dimension Therapeutics, Inc.P Purchase	Director	PPurchase	+200K sh	$13.00	+$2.6M	5,397,698
2015-10-27	Dimension Therapeutics, Inc.Series A Preferred StockC Conversion	Director	CConversion	−9.5M sh	—	—	0
2015-10-27	Dimension Therapeutics, Inc.Series B Preferred StockC Conversion	Director	CConversion	−5.69M sh	—	—	0
2012-06-22	ChemoCentryx, Inc.Stock Option (right to buy)A Award	Director	AAward	+12.5K sh	—	—	12,500

Recent filings

Accepted (ET)
Feb 174
Gupta Rishi0001537370-26-000001
SEC(opens sec.gov)
Aug 84
Gupta Rishi0001415889-25-021337
SEC(opens sec.gov)
Feb 104
Gupta Rishi0001415889-25-003519
SEC(opens sec.gov)
Jul 24
Gupta Rishi0001415889-24-018925
SEC(opens sec.gov)
May 204
Gupta Rishi0000947871-24-000501
SEC(opens sec.gov)
Feb 204/A
Gupta Rishi0001415889-24-004488
SEC(opens sec.gov)
Feb 154
Gupta Rishi0001415889-24-004016
SEC(opens sec.gov)
Oct 174
Gupta Rishi0001209191-23-053004
SEC(opens sec.gov)
Jul 244
Gupta Rishi0000947871-23-000778
SEC(opens sec.gov)
May 194
Gupta Rishi0000947871-23-000608
SEC(opens sec.gov)
May 154
Gupta Rishi0000947871-23-000585
SEC(opens sec.gov)

Companies

Address

C/O ENLIVEN THERAPEUTICS, INC. 6200 LOOKOUT ROAD

BOULDER, CO, 80301